Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial

BACKGROUND: Patients with hormone receptor-positive, HER2-negative breast cancer who have residual invasive disease after neoadjuvant chemotherapy (NACT) are at a high risk of relapse. PENELOPE-B was a double-blind, placebo-controlled, phase III trial that investigated adding palbociclib (PAL) for t...

Descripción completa

Detalles Bibliográficos
Autores principales: Galactionova, Katya, Loibl, Sibylle, Salari, Paola, Marmé, Frederik, Martin, Miguel, Untch, Michael, Bonnefoi, Hervé R., Kim, Sung-Bae, Bear, Harry D., McCarthy, Nicole, Gelmon, Karen A., García-Sáenz, José A., Kelly, Catherine M., Reimer, Toralf, Toi, Masakazu, Rugo, Hope S., Gnant, Michael, Makris, Andreas, Burchardi, Nicole, Schwenkglenks, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9484462/
https://www.ncbi.nlm.nih.gov/pubmed/36132153
http://dx.doi.org/10.3389/fonc.2022.886831

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9484462/
https://www.ncbi.nlm.nih.gov/pubmed/36132153
http://dx.doi.org/10.3389/fonc.2022.886831

Ejemplares similares